Fiche publication
Date publication
février 2026
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle
,
Dr PINEL Sophie
,
Pr BOURA Cédric
,
Dr REPPEL Loïc
Tous les auteurs :
Lamorlette C, Boura C, Pinel S, Bensoussan D, Dotti G, Alanio C, Reppel L
Lien Pubmed
Résumé
Glioblastoma (GBM) is the most common and aggressive brain tumor in adults, and current treatments remain poorly efficient. In this context, immunotherapies may represent promising strategies. However, their efficacy is often limited by a strong negative impact of the tumor microenvironment (TME) of glioblastoma. Several factors such as tumor cells mutational profile, previous lines of conventional treatments, or biological factors, have been shown as involved in TME modulation. In this review, our goal is to give an overview of the main modulating factors of the TME of glioblastoma tumors. We will also highlight the importance of developing complex and integrative models to study this microenvironment. At the end, by highlighting critical components of the glioblastoma microenvironment, this review aims to support the development of next-generation, more effective and personalized immunotherapeutic strategies.
Mots clés
glioblastoma, immunotherapy, microenvironment, modulating factors, myeloid cells
Référence
Front Immunol. 2026 02 10;17:1755073
